S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Paychex Is Immune To The Global Systemic Woes

Friday, October 1, 2021 | Thomas Hughes
Paychex Is Immune To The Global Systemic Woes

Buy Paychex For Growth In Q4 And 2022

It is no doubt that the labor market is strong and the Paychex (NASDAQ: PAYX) result proves it. While there are still lingering issues with the labor market, employment conditions have surpassed pre-COVID levels and have companies like PayChex and Cintas on track for sustained growth. What this means for investors in these troubled times is a stock with far less exposure to the woes plaguing the S&P 500 than many others in the market. If you’re looking for a place to park some money with an expectation for growth, dividends, and dividend growth Paychex is a fine choice.

Paychex Results Give Evidence Of Leverage

Paychex’s fiscal Q1 earnings report gives evidence of something we've been expecting for the last few quarters and that is leverage. While the average receipt per client fell at the height of the pandemic the number of clients grew. Now, with workforces slowly rebuilding to pre-COVID levels, the business has exceeded those levels for Paychex and is expected to continue growing. 

The company reported $1.08 billion in consolidated revenue which is good for a gain of 15.9% over last year and 8.8% over 2019. The revenue beat the consensus by $40 million or 370 basis points and led the company to increase guidance. On a segment basis, Management Solutions led with a 17% increase driven by an increased client base, improved penetration, and a higher check average per client. The PEO and Insurance segment grew by 14% due to greater numbers of on-site employees.

Moving down the report, the company says it was able to decrease expenses by 1% across the network or -4% on an adjusted basis. This helped to drive a high double-digit increase in operating income and strength on the bottom line. The company's GAAP earnings of  $0.92 beat the consensus by $0.11 while the adjusted earnings of  $0.89 beat the consensus by  $0.09 and both helped improve an already strong capital position.

Turning to the guidance, the company expects full-year 2022 revenue growth in a range of 8% versus the 7.37% expected by the analyst. We see upside risk in these numbers due to ongoing economic expansion within the United States and the company’s obvious leverage. Margins are expected to widen to a range of 38% to 39% and drive EPS growth to 12% to 14% versus the 11.16% consensus currently indicated by Marketbeat.com.

Paychex Is A Paycheck For Dividend Growth Investors

Paychex is a cash-generating machine and one that is growing and paying a healthy dividend that is also growing. The stock currently yields about 2.45% with only one red flag. The payout ratio is 78% of earnings but that is mitigated by a very very healthy balance sheet. The company has incredibly low levels of debt, is leveraged at less than 1X earnings, has a high coverage ratio, is net cash, and has plenty of free cash flow to continue raising the dividend for another 10 years. The next distribution increase is expected in the fiscal fourth quarter and should run in the range of 8 to 10%.

The Technical Outlook: Paychex Pops, Triggers Buy Signal

Paychex price action popped more than 5% in the wake of the Q1 earnings report and may have gone higher if not for broad market selling on the same day. Price action created a strong candle with a large lower shadow confirming support at the short-term moving average. Support is confirmed by the indicators as well, both MACD and stochastic are showing bullish crossovers in tandem with the move above the short-term moving average which is a combination that we consider to be a strong buy signal. Price action should move up to retest the recent highs near $120 fairly soon and then break out to new highs before the end of the year. 

Paychex Is Immune To The Global Systemic Woes

Should you invest $1,000 in Paychex right now?

Before you consider Paychex, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Paychex wasn't on the list.

While Paychex currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Paychex (PAYX)2.1$122.45-2.1%2.16%36.34Hold$109.18
Compare These Stocks  Add These Stocks to My Watchlist 

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Most Read This Week

Recent Articles

Search Headlines:
MarketBeat Minute Podcast

Each market day you'll get a one-minute market summary to help you invest wisely.

Subscribe to MarketBeat Minute


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.